{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-105023","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.568481+00:00","generated_at":"2026-05-17T17:42:18.863959+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Alector Q2 net loss $30.5M; cash $307.3M; Phase 3 latozinemab data mid-Q4","bullets":["Net loss $30.5M ($0.30/sh) vs $38.7M ($0.40/sh) in Q2 2024; revenue $7.9M down from $15.1M.","Cash, cash equivalents, and investments $307.3M, providing runway into H2 2027.","On track to report topline data from INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN by mid-Q4 2025.","Guidance updated: collaboration revenue $13-18M, R&D expenses $130-140M, G&A $55-65M for FY2025.","Neil Berkley appointed interim CFO; USPTO issued patent for latozinemab treatment method."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-105023","json":"https://secwatch.observer/filing/0000950170-25-105023.json","markdown":"https://secwatch.observer/filing/0000950170-25-105023.md","text":"https://secwatch.observer/filing/0000950170-25-105023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000095017025105023/0000950170-25-105023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000095017025105023/alec-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:42:18.863959+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}